Table 1:
Distribution of tumor and patient characteristics among breast cancer recurrence cases and controls by ER/TAM group among 1682 subjects in the population-based case control study of women age 35–69, diagnosed with Stage I–III breast cancer between 1985–2001, and registered with the Danish Breast Cancer Group
| Patient Characteristic | ER+/TAM+, N (%) | ER−/TAM−, N (%) | ||||||
|---|---|---|---|---|---|---|---|---|
| Case | Control | Case | Control | |||||
| Nuclear Survivin Expression | ||||||||
| >75th%tile | 82 | (20) | 82 | (20) | 76 | (31) | 68 | (28) |
| 50th-75th %tile | 94 | (23) | 84 | (20) | 43 | (17) | 49 | (20) |
| <50th %tile | 236 | (57) | 245 | (60) | 127 | (52) | 126 | (52) |
| Missing | 129 | 130 | 54 | 57 | ||||
| Nuclear Survivin Expression | ||||||||
| ≥50th %tile | 176 | (43) | 166 | (40) | 119 | (48) | 117 | (48) |
| <50th %tile | 236 | (57) | 245 | (60) | 127 | (52) | 126 | (52) |
| Missing | 129 | 130 | 54 | 57 | ||||
| Cytoplasmic Survivin Expression | ||||||||
| >75th%tile | 103 | (25) | 108 | (27) | 61 | (25) | 61 | (25) |
| 50th-75th %tile | 112 | (27) | 104 | (25) | 67 | (27) | 64 | (26) |
| <50th %tile | 197 | (48) | 199 | (48) | 118 | (48) | 118 | (49) |
| Missing | 129 | 130 | 54 | 57 | ||||
| Cytoplasmic Survivin Expression | ||||||||
| ≥50th %tile | 215 | (52) | 212 | (52) | 128 | (52) | 125 | (51) |
| <50th %tile | 197 | (48) | 199 | (48) | 118 | (48) | 118 | (49) |
| Missing | 129 | 130 | 54 | 57 | ||||
| Joint Survivin Expression | ||||||||
| Yes | 134 | (33) | 121 | (29) | 76 | (31) | 72 | (29) |
| No | 278 | (67) | 290 | (71) | 170 | (69) | 171 | (71) |
| Missing | 129 | 130 | 54 | 57 | ||||
| Cytoplasmic:Nuclear Ratio | ||||||||
| ≥5 | 73 | (41) | 69 | (42) | 33 | (28) | 19 | (16) |
| <5 | 103 | (59) | 97 | (58) | 86 | (72) | 98 | (84) |
| Diagnosis year | ||||||||
| 1985–1993 | 235 | (43) | 234 | (43) | 107 | (36) | 100 | (33) |
| 1994–1996 | 113 | (21) | 112 | (21) | 81 | (27) | 83 | (28) |
| 1997–2001 | 193 | (36) | 195 | (36) | 112 | (37) | 117 | (39) |
| Age category at diagnosis | ||||||||
| 35–44 | 16 | (3.1) | 13 | (2.4) | 68 | (23) | 58 | (19) |
| 45–54 | 116 | (21) | 111 | (21) | 120 | (40) | 113 | (38) |
| 55–64 | 286 | (53) | 281 | (52) | 82 | (27) | 86 | (29) |
| 65–69 | 123 | (23) | 136 | (25) | 30 | (10) | 43 | (14) |
| Menopausal status at diagnosis | ||||||||
| Premenopausal | 34 | (6.3) | 34 | (6.3) | 121 | (40) | 121 | (40) |
| Postmenopausal | 507 | (94) | 507 | (94) | 179 | (60) | 179 | (60) |
| UICC tumor stage at diagnosis | ||||||||
| I | 9 | (1.7) | 9 | (1.7) | 25 | (8.3) | 25 | (8.3) |
| II | 250 | (46) | 250 | (46) | 153 | (51) | 153 | (51) |
| III | 282 | (52) | 282 | (52) | 122 | (41) | 122 | (41) |
| Histological grade | ||||||||
| I | 108 | (25) | 144 | (35) | 27 | (11) | 23 | (10) |
| II | 234 | (54) | 215 | (52) | 125 | (49) | 98 | (43) |
| III | 92 | (21) | 57 | (14) | 103 | (40) | 106 | (47) |
| Missing | 107 | 125 | 45 | 73 | ||||
| Surgery Type | ||||||||
| Breast-conserving surgery | 58 | (11) | 71 | (13) | 47 | (16) | 56 | (19) |
| Mastectomy | 483 | (89) | 470 | (87) | 252 | (84) | 244 | (81) |
| Missing | 1 | 0 | ||||||
| Radiation therapy | ||||||||
| Yes | 183 | (34) | 191 | (35) | 128 | (44) | 123 | (47) |
| No | 358 | (66) | 350 | (65) | 166 | (56) | 137 | (53) |
| Missing | 6 | 40 | ||||||
| Systemic adjuvant chemotherapy | ||||||||
| Yes | 70 | (13) | 65 | (12) | 248 | (83) | 188 | (63) |
| No | 471 | (87) | 476 | (88) | 52 | (17) | 112 | (37) |
| Tamoxifen protocol, years | ||||||||
| 1 | 257 | (48) | 261 | (48) | ||||
| 2 | 98 | (18) | 92 | (17) | ||||
| 5 | 186 | (34) | 188 | (35) | ||||